The study was undertaken because (1) it was unclear how exactly SGLT2 inhibitors affect renal hemodynamics in patients with T2D whose renal physiology differs from that of previously studied T1D patients with hyperfiltration and (2) it was unknown whether the effects of SGLT2 inhibitors are diminished in response to glucose lowering. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.